
Postdoc in Jeffrey Ravetch lab @RockefellerUniv
New York
Joined March 2020
- Tweets248
- Following284
- Followers206
- Likes1.8K
Lucas Blanchard retweeted
Our team @MSKCancerCenter @RockefellerUniv are excited to see our completed #bladderCA trial using intravesical anti-CD40 targeting in press. Ongoing anti-CD40 PH3 trial for NMIBC opened!
@UrologyMSK @juanosoriomd @DrRosenbergMSK @eugene_pietzak
@UroOnc
aacrjournals.org/clincancerr…
Lucas Blanchard retweeted
Excited to share our study, published today in @CCR_AACR
Can we harness CD40 agonism to treat bladder cancer? And how spatial immune organization within tumors correlate with response? We report findings from a phase I trial of our Fc-engineered CD40 agonist.
🧵🪡 link 👇
Lucas Blanchard retweeted
Now online: Spatial Immune Organization Associates with Response to CD40 Agonism in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer: A Phase I Trial doi.org/10.1158/1078-0432.CC…
Lucas Blanchard retweeted
Targeting Myeloid Cells for Cancer Immunotherapy: doi.org/10.1158/2326-6066.CI… @juanosoriomd @LucasBlch
Lucas Blanchard retweeted
Our review on myeloid-targeting therapies in cancer immunotherapy is out in @CIR_AACR ! 🔬
We highlight recent advances, key challenges, and opportunities for translating these tx to the clinic.
Huge thx to @LucasBlch for leading this work and Andrew Mijacika!
Lucas Blanchard retweeted
Thrilled to share our new publication on the first-in-human phase 1 trial of intratumoral Fc-engineered CD40 agonistic antibody 2141-V11 in metastatic cancer. Over 10 years of preclinical work led to this moment, made possible by an amazing team! 🧵 🪡 cell.com/cancer-cell/fulltex…
Lucas Blanchard retweeted
Happy to share our latest #review on #neoadjuvantimmunotherapy: an extensive overview of current and emerging data in NSCLC, TNBC, GI + bladder cancers, melanoma and many more: written with close friends and KOLs published today in @NatureCancer @lab_kok
doi.org/10.1038/s43018-025-0…
Lucas Blanchard retweeted
🚨 REVIEW🚨
Vignali & colleagues outline the various contributions of #Tregs to tumour progression & highlight ways in which they represent an attractive #nextgen immunotherapeutic target.
📖 👇
bit.ly/4mVxI8n
Thank you ACIR for highlighting our recent study ! 🎉
Blanchard and Vina et al. investigated mechanisms by which anti-CTLA-4 mAbs modulate tumor-associated high endothelial venules (TA-HEVs), which are important for supporting lymphocyte entry into tumors. bit.ly/4dNZyzu @LucasBlch
2
78
We have previously shown that TA-HEVs are critical blood vessels that mediate lymphocyte entry into tumors during cancer immunotherapy, which suggested that strategies increasing TA-HEVs could improve treatment efficacy in non-responsive 'cold' tumors.
sciencedirect.com/science/ar…
26
Lucas Blanchard retweeted
#ResultatScientifique🔎| Un nouvel anticorps pour améliorer l’efficacité de l’immunothérapie
🤝@CNRS @CNRS_Toulouse @Univ_Toulouse
✍️ Jean-Philippe Girard
📕 @CellRepMed | cell.com/cell-reports-medici…
insb.cnrs.fr/fr/cnrsinfo/un-…
Lucas Blanchard retweeted
🚨 PLEASE SHARE! Early-career bladder cancer researchers: Apply now for BCAN's 2025 Young Investigator Awards! $75K in funding, mentorship, and networking opportunities await. Advance your research and career. 🧬 Deadline: Feb 21, 2025. Click for info: bcan.org/bcan-research/grant…
[AI image]
Lucas Blanchard retweeted
Very excited to see this in print! Such promising outcomes for immune cold #sarcomas with Botensilimab Plus Balstilimab ascopubs.org/doi/10.1200/JCO… @Agenus_Bio @CUCancerCenter
Lucas Blanchard retweeted
Long awaited practice-changing results from ph 3 CM8HW now out in @TheLancet. Nivo/ipi sign better than nivo mono in dMMR mCRC
@sara_lonardi1 @bmsnews #GI25
thelancet.com/journals/lance…
Lucas Blanchard retweeted
Just published📢 Our new forum article on Fc-optimized checkpoint antibodies for cancer therapy. New to immunotherapy and antibody engineering? This one’s for you! Co-authored with Alan Korman. @TrendsMolecMed #CancerImmunotherapy #FcEngineering
sciencedirect.com/science/ar…
Lucas Blanchard retweeted
Check out our latest paper “Differentiation fate of a stem-like CD4 T cell control immunity to cancer”, led by @Maria_Carden1 now live @Nature tinyurl.com/33d24k89 . This work examines how CD4 T cell differentiation dictates the outcome of the cancer response. Thread below
Lucas Blanchard retweeted
Plz check out our new paper on pre-op SRS and the immune microenvironment of human brain metastases. nature.com/articles/s41467-0…
Big team effort: @careyjans @meghatron2016 @HaydnKissick @Maria_Carden1 @MohammadKhanMD and many more.
Lucas Blanchard retweeted
How do T cells reach melanoma brain tumors?
Using in vivo microscopy, we discovered a new route for T cells to enter the brain via distinct peri-tumoral venous vessels.
Our newest paper is now online @ImmunityCP.
authors.elsevier.com/sd/arti…
A 🧵👇
Grateful and honored that our project on the therapeutic targeting of regulatory T cells (Tregs) was selected by @BladderCancerUS 🙏🏻
Let’s deplete these Tregs !
@RockefellerUniv
Welcome to the cohort, Lucas Blanchard, PhD (@LucasBlch)! Dr. Blanchard has received a BCAN 2024 Young Investigator Award. You can learn more about his research proposal and the award here: bcan.org/bcan-announces-four…
Lucas Blanchard retweeted
To improve agonist CD40 Abs for clinical use, Osorio, Knorr, Weitzenfeld, et al. evaluated 2141-V11, an Fc-engineered anti-CD40 (with optimized FcγRIIB binding) in a phase 1 study (12 patients). bit.ly/4cJhCcg @RockefellerUniv






















